卡培他滨的合成工艺改进

以D-核糖为起始原料经缩酮化、酯化、NaBH_4在DMSO与石油醚(1∶0.5∶1.5)还原、水解、无水醋酸钠催化酰化制备中间体(6a6b)与5-氟胞嘧啶进行Silyl反应制备同一构型的5′-脱氧-2′,3′-二-O-乙酰基-5-氟胞苷(7),(7)再与氯甲酸正戊酯进行酰胺化,最后水解去除乙酰基得到卡培他滨,总收率42.17%。HPLC纯度为99.81%。该新合成方法原料廉价易购、反应条件温和、操作简单,适合工业化生产。     

抗肿瘤药物卡培他滨的合成工艺改进

本文以价廉易得的D-核糖为起始原料,经缩酮化保护、磺酰化,1,4-二氧六环做溶剂的条件下,使用硼氢化钾还原、再经水解、乙酰化反应得到关键中间体1,2,3-三-O-乙酰基-5-脱氧-D-呋喃核糖,再与5-氟胞嘧啶进行Silyl反应制备5′-脱氧-2′,3′-二-O-乙酰基-5-氟胞苷,与氯甲酸正戊酯进行酰胺化,水解得到目标化合物卡培他滨(1),结构经¹HNMR、¹³CNMR以及MS表征,总产率49.69%(以D-核糖计),HPLC测得纯度100.00%。该合成方法原料廉价易购、反应条件温和,改进后的路线操作简单,绿色环保,适合工业化生产。     

一种新的合成氯法拉滨的方法

氯法拉滨是临床上唯一可以特异性地治疗儿童白血病的药物,2004年被美国食品和药物管理局批准上市.由于现有合成方法存在路线长、收率低和α/β异构体难以分离等问题,限制了该药物的广泛使用和进一步研究.以廉价且商品化的2-氯腺苷为原料,通过乙酸酐保护糖环上的3个羟基,在水合肼和乙酸作用下,选择性地脱除2'位的乙酰基.然后,以商品化的氟代试剂二乙胺基三氟化硫(DAST)进行2'位羟基的氟代反应,再使用NH3/MeOH饱和溶液脱除乙酰基可得氯法拉宾.这4步反应的总收率为49%,且得到的产品全部为β构型.同时,还发现2位取代基的位阻越大,越有利于选择性脱除2'位的乙酰基.本方法可以在克级规模上进行生产,收率无下降,同时中间体及产物的纯化不需要通过柱层析分离,显示出良好的应用前景?.     

以鸟苷为原料合成2-异肌苷

以廉价的鸟苷为原料,经过乙酰基保护糖环上的羟基,再和POCl3反应,将6-位羰基转化为氯原子,继而还原脱除氯原子,然后在亚硝酸异戊酯作用下发生重氮化反应,将2-位氨基转化为羟基,最后脱除乙酰基,以5步和56％的总收率得到2-异肌苷.重氮化优化的反应条件是:6倍量的亚硝酸异戊酯为重氮化试剂、CHCl3/H2 O为混合溶剂...     

无溶剂、无催化剂条件下α-腺嘌呤阿拉伯糖苷的合成

为了发展有效合成α-腺嘌呤阿拉伯糖苷的方法,以1,2,3,5-四-O-乙酰基-β-D-阿拉伯糖和6-氯嘌呤为原料,在微波辐射和无溶剂、无催化剂条件下反应得到中间体9-α-D-(2',3',5'-三-O-乙酰基)阿拉伯呋喃糖基-6-氯嘌呤,收率85%。该中间体物在Na2CO3催化下脱除乙酰基,然后"一锅"加入饱和的NH3/CH3OH溶液氨解,以90%的收率得到α-腺嘌呤阿拉伯糖苷。关键中间体9-α-D-(2',3',5'-三-O-乙酰基)阿拉伯呋喃糖基-6-氯嘌呤的合成反应规模可以扩大到100 g。类似地合成α-2-氟腺嘌呤阿拉伯糖苷和α-2-氨基腺嘌呤阿拉伯糖苷。     

3-氰基-5-甲氧基苯磺酰氯的合成

3-氰基-5-甲氧基苯磺酰氯是合成多种具有药物活性分子的重要中间体。本文以3,5-二硝基苯甲酸为起始原料,经过取代,酰胺化,脱水,硝基还原,重氮化以及磺化首次合成了目标化合物,其结构经MS和1H NMR确证。该方法原料廉价易得,操作简便易控且收率较高,反应总收率为65.9%。     

BF_3·Et_2O催化Pechmann反应一锅合成3-氨基-5,7-二羟基-4-甲基香豆素

3-氨基-5,7-二羟基-4-甲基香豆素(4)是一种新的重要有机合成中间体,可用于多种潜在生物活性物质的合成。本文将间苯三酚与2-乙酰氨基乙酰乙酸乙酯(2)在BF_3·Et_2O催化下,经串联的Pechmann缩合反应和脱乙酰基反应一锅合成4。化合物2由乙酰乙酸乙酯经成肟、还原、酰化反应制得。中间体和目标物的结构均经1H NMR、13C NMR、MS表征。该方法具有原料廉价易得、步骤短、操作简便易控、反应条件温和、收率高的优点。     

4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸的合成工艺研究

4-(E-3-乙氧基-3-氧代-1-丙烯-1-基)苯基硼酸是一种重要的有机中间体。本文以4-甲酰基苯硼酸为起始原料,经Wittig-Horner反应合成了标题化合物。该合成方法未见文献报道,原料廉价易得,操作简便易控,反应条件温和,产品纯度较高,适合工业化生产。反应收率为78.8%。     

杨梅素-3-O-β-D-乳糖的合成方法优化

杨梅素是一种主要用于抗炎的多酚类黄酮化合物,为改善其水溶性和稳定性,合成了杨梅素-3-O-β-D-乳糖,并开发了一条高效的合成路线。首先以杨梅苷为起始原料,对杨梅苷的5位、7位、3′位、4′位和5′位酚羟基进行保护,形成五苄基保护的杨梅苷。然后脱除3位鼠李糖,再与乙酰基保护的乳糖溴苷反应,最后通过依次脱去乙酰基和苄基得到目标化合物。经过路径优化,最终以更高效的方法合成了杨梅素-3-O-β-D-乳糖,减少了副产物的生成,提高了原合成路线总收率,此方法的总产率为44.5%。该路径得到了2个新型的杨梅素衍生物中间体。目标化合物的结构均经过¹H NMR,¹³C NMR和HR-MS(ESI)确证。     

无金属催化合成2,6-二氯嘌呤核苷和2-氯腺苷

提出了合成2,6-二氯嘌呤核苷和2-氯腺苷的新方法。 以商品化的2,6-二氯嘌呤和四乙酰核糖为原料,在5%(摩尔分数)三氟甲磺酸催化下,得到缩合物2',3',5'-三-O-乙酰基-2,6-二氯嘌呤核苷。 缩合物在浓H₂SO₄催化下,以89%的收率得到2,6-二氯嘌呤核苷;在NH₃/CH₃OH体系中氨解和脱除乙酰基,以92%的收率得到2-氯腺苷。 反应规模可以扩大到100 g,收率未降低。 该方法原料价格低廉,避免使用重金属催化剂,操作简便,中间体及产物可以通过结晶的方法纯化得到,显示出潜在的应用价值。     

A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients

Capecitabine is a prodrug of 5‐flurouracil, employed as a broad spectrum chemotherapeutic agent. It is also used as monotherapy or a combination chemotherapy agent for the treatment of colorectal cancer. Capecitabine is administered in combination with oxaliplatin and hence it is essential to determine that co‐administration does not affect its metabolism. To determine the plasma concentration of capecitabine a simple HPTLC method was developed and validated. Blood samples from 12 patients with colorectal cancer were collected and analyzed by the HPTLC method with a reference internal standard. Out of these 12 patients, six were treated with capecitabine monotherapy and another six were treated with capecitabine + oxaliplatin combination therapy. The results of analysis indicated that there was no significant drug–drug interaction and the co‐administration of oxaliplatin did not affect the metabolism of capecitabine. This method is sensitive, robust and specific and allows analysis of multiple samples simultaneously, making it suitable for therapeutic drug monitoring of capecitabine.     

An efficient route for the preparation of a 21-fluoro progestin-16 alpha,17 alpha-dioxolane,a high-affinity ligand for PET imaging of the progesterone receptor

Two different synthetic routes were explored for the synthesis of fluoro furanyl norprogesterone (FFNP) 1, a high-affinity ligand for the progesterone receptor (PgR) that is being developed as a PET imaging agent for PgR-positive breast cancer. Both approaches proceed through a key intermediate, triol 5. The first approach, starting from keto-ketal 2, employed a dioxenyl group as a synthon for installing a corticosteroid side chain in keto-alcohol 4. The second approach, starting from propargylic acetate 12b, involved the application of a two-step method, a Pd(II)-catalyzed oxidative rearrangement followed by a base-catalyzed acetate rearrangement of the intermediate unsaturated acetate 13b, to generate the requisite corticosteroid side chain in keto-acetate 14b. This intermediate was further elaborated to the final product 1 via efficient dihydroxylation with potassium permangnate, furan acetalization with scandium triflate, and mesylation and fluorination reactions. The palladium-catalyzed route is considerably more efficient than the dioxene approach for the synthesis of key intermediate triol 5, and the scandium triflate-catalyzed acetalization, in particular, led to a considerable improvement in the overall yield of the endo furan acetal alcohol 16a. This route provides a major improvement in the overall yield of the final progestin target, FFNP 1.     

Improved and large-scale synthesis of 10-methyl-aplog-1, a potential lead for an anticancer drug

10-Methyl-aplog-1 (1), a simplified analog of tumor-promoting aplysiatoxin, is a potential lead for cancer therapy that exhibits marked and selective growth inhibitory effects against several human cancer cell lines and negligible tumor-promoting activity in vivo. However, more detailed evaluations of its toxicity and anticancer activity in vivo are hampered by supply problems associated with a non-optimal synthetic method. We here addressed this issue through a more practical and reliable synthetic method that afforded several hundred milligrams of 1 with high purity (>98%) in 23 steps from commercially available m-hydroxycinnamic acid with an overall yield of 1.1%. The utilization of two key reactions, substrate-controlled epoxidation and the oxidative cleavage of alkene with a free hydroxyl group, successfully reduced the existing five synthetic steps and markedly improved the handling of large amounts of intermediates. We also demonstrated for the first time that such an analog was synthetically accessible in reliable quantities and also that this large supply could advance in vivo trials for the treatment of cancer.     

A simple and efficient synthesis of the valsartan

Valsartan 1, one of the most important agents used in antihypertensive therapy today, was synthesized starting from L-valin methyl ester hydrochloride 2 through four steps in an overall yield of 60%. The key step involves the palladium-catalyzed Suzuki coupling. This method overcomes many of the drawbacks associated with the previously reported syntheses and is more suitable for industrial production.     

Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent

An amphiphile prodrug, 5′-deoxy-5-fluoro-N⁴-(palmityloxycarbonyl) cytidine or 5′-deoxy-5-fluoro-N⁴-(hexadecanaloxycarbonyl) cytidine (5-FCPal), consisting of the same head group as the commercially available chemotherapeutic agent Capecitabine, linked to a palmityl hydrocarbon chain via a carbamate bond is reported. Thermal analysis of this prodrug indicates that it melts at ∼115 °C followed quickly by degradation beginning at ∼120 °C. The neat solid 5-FCPal amphiphile acquires a lamellar crystalline arrangement with a d-spacing of 28.6 ± 0.3 Å, indicating interdigitation of the hydrocarbon chains. Under aqueous conditions, solid 5-FCPal is non-swelling and no lyotropic liquid crystalline phase formation is observed. In order to assess the in vitro toxicity and in vivo efficacy in colloidal form, solid lipid nanoparticles (SLNs) with an average size of ∼700 nm were produced via high pressure homogenization. The in vitro toxicity of the 5-FCPal SLNs against several different cancer and normal cell types was assessed over a 48 h period, and IC₅₀ values were comparable to those observed for Capecitabine. The in vivo efficacy of the 5-FCPal SLNs was then assessed against the highly aggressive mouse 4T1 breast cancer model. To do so, the prodrug SLNs were administered orally at 3 different dosages (0.1, 0.25, 0.5 mmol/mouse/day) and compared to Capecitabine delivered at the same dosages. After 21 days of receiving the treatments, the 0.5 mmol dose of 5-FCPal exhibited the smallest average tumour volume. Since 5-FCPal is activated in a similar manner to Capecitabine via a 3 step enzymatic pathway with the final step occurring preferentially at the tumour site, formulation of the prodrug into SLNs combines the advantage of selective, localized activation with the sustained release properties of nanostructured amphiphile self-assembly and multiple payload materials thereby potentially creating a more effective anticancer agent.     

Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review

Capecitabine (Xeloda) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas.     

Synthesis of 1alpha-hydroxyvitamin D5 using a modified two wavelength photolysis for vitamin D formation

[reaction: see text] 1Alpha-hydroxyvitamin D5 (1) is a promising chemopreventive agent for breast cancer and is being developed as a drug. We report a synthesis for this vitamin D analogue which uses a photochemical method for the B-ring opening, leading to the conjugated triene system. The precursor 7-dehydrositosteryl acetate (4) obtained through a one-pot, five-step procedure, was completely free of the 4,6-diene isomer that usually forms in the 5,7-diene synthesis. The pre-vitamin isomer (11) was generated using a modified two-wavelength photolysis procedure that increases the yield for this step more than 3-fold compared to classically used photolysis. The 1alpha-hydroxylation step was performed on the 3-triethylsilyl-trans-vitamin D5 (17) obtained via the sulfur dioxide adduct of cis-vitamin D5, in an overall yield of 48%. Photoisomerization and deprotection completed the synthesis.     

The first radical method for the introduction of an ethynyl group using a silicon tether and its application to the synthesis of 2'-deoxy-2'-C-ethynylnucleosides

A novel radical method for the stereoselective introduction of an ethynyl group has been developed. When a solution of ethynyldimethylsilyl (EDMS) or [2-(trimethylsilyl)ethynyl]dimethylsilyl (TEDMS) ethers of trans-2-iodoindanol was treated with Et(3)B followed by tetrabutylammonium fluoride in toluene, atom transfer 5-exo-cyclization and subsequent elimination occurred to give cis-2-ethynylindanol in high yield. The method was shown to be useful in the introduction of an ethynyl group in various five- and six-membered-ring iodohydrins. Furthermore, 2'-deoxy-2'-C-ethynyluridine (6) and -cytidine (7), which were designed as novel antimetabolites, were readily synthesized by using this method as the key step. This would be the first example in which a radical reaction was used for introducing an ethynyl group.     

Synthesis and antitumor activity of 9-methyl-10-hydroxycamptothecin

A novel camptothecin analogue, 9-methyl-10-hydroxycamptothecin （4）, was unexpectedly synthesized from 10-hydroxycamptothecin in two steps. The key step included an efficient Mannich-type reaction. The overall yield was 47.2%. An ether analogue of 4, 9-methyl-10-benzylaminomethoxycamptothecin （5）, was also prepared. These new camptothecin analogues were evaluated for in vitro cytotoxicity against four human cancer cell lines, and exhibited more potent antitumor activities than contrals camptothecin and topotecan against several cancer cells.     

Total synthesis of flocoumafen via knoevenagel condensation and intramolecular ring cyclization: general access to natural products

The total synthesis and structure determination of cis- and trans-flocoumafen was described. The key synthetic steps involve Knoevenagel condensation with p-methoxybenzaldehyde, in situ decarboxylation and intramolecular ring cyclization to construct the tetralone skeleton. Stereospecific reduction of the O-alkylated ketone 13 afforded good yield of precusor alcohol 5. Final coupling of alcohol 5 with 4-hydroxy-coumarin yielded flocoumafen (1). Separation and structure determination of cis- and trans-flocoumafen through 2D NMR analyses-assisted computer simulation techniques for the evaluation of anticoagulant activities are reported for the first time. This method is useful for generating the core tetralone skeleton of 4-hydroxycoumarin derivatives and provides a generalized access to various warfarin type anticoagulants.